March 27th, 2020 | 14:20 CET
Drägerwerk or Micro-X - how do investors benefit from the Corona Pandemic?
The current Corona Pandemic is challenging people around the globe. Doctors and medical staff are under particular strain. For some time now, it has become clear that there is a lack of material and equipment to withstand a large onslaught of infected Covid-19 patients. In order to slow down the spread of the virus, the population is urged to avoid social contacts. Manufacturers of equipment and materials for the medical sector are now being flooded with orders to compensate for the shortage, and investors have the opportunity to make a financial investment.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
DE0005550636 , AU000000MX15
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Federal government fills supply gap
The ventilators and medical protective equipment of Drägerwerk AG & Co. KGaA are in great demand. Two weeks ago, the company received a major order from the German government. According to the announcement, the delivery of 10,000 ventilators and protective equipment for medical personnel was agreed. The delivery will cover the next 12 months. This order is directly related to the spread of the corona virus and will be used to supply the healthcare system.
Product to combat shortages
In addition to ventilators, X-ray equipment is also needed to monitor the course of the disease in the patient's lungs. In recent years, the Australian company Micro-X Limited has developed a mobile X-ray unit that is now going into series production. The device is called the Carestream DRX Revolution Nano. The advantage is that the device can be moved, which increases the treatment comfort of the patients.
Based on the demand for the devices, the company will adapt its growth strategy and immediately initiate operational measures originally planned for a later date, Micro-X recently announced. As hospitals are now the focus of events and gaps in medical care are becoming apparent, more money is expected to flow into healthcare now and in the future.
Sales increase significantly
While Drägerwerk is a traditional billion-dollar company, at Micro-X investors can enter a growth story that is now experiencing high demand. In the past fiscal year, the company generated sales of AUD 1.9 million and was already able to announce incoming orders of AUD 2.4 million in the first quarter of 2020.
Micro-X's market capitalisation is currently AUD 31.25 million at the closing price of AUD 0.125 on the home exchange ASX. The shares of the company are not (yet) listed in Germany but information on the security is available and trading on the ASX is possible via the following details: ISIN: AU0000MX15, WKN: A2ACCY, ASX: MX1 or via the website: micro-x.com.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
